Can I read Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia on EtoBox?

Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia by Faryal Khamis; Hanan Al Naabi; Adil Al Lawati; Zaiyana Ambusaidi; Mariam Al Sharji; Umkulthum Al Barwani; Nenad Pandak; Zakariya Al Balushi; Maher Al Bahrani; Issa Al Salmi; Ibrahim Al-Zakwani is a Medicine article available to read on EtoBox.

What is Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia about?

## Objective: To evaluate the therapeutic effectiveness of favipiravir combined with inhaled interferon beta-1b in adult patients hospitalized with moderate to severe covid-19 pneumonia. ## Methods: A randomized, open-label controlled trial of oral favipiravir in adults hospitalized with moderate to severe covid-19 pneumonia from june 22nd 2020 to august 13th 2020 was conducted. patients were randomly assigned to receive either a combination of favipiravir with interferon beta-1b by inhalation aerosol or hydroxychloroquine (hcq). the outcome endpoints included improvement in inflammatory markers, lower length of hospital stay (los), discharges and lower overall 14-day mortality. ## Results: A total of 89 patients underwent randomization with 49% (n = 44) assigned to favipiravir and 51% (n = 45) assigned hcq. the overall mean age was 55 ± 14 years and 58% (n = 52) were males. there were no significant differences in the inflammatory biomarkers at hospital discharge between the two groups; c-reactive protein (p = 0.413), ferritin (p = 0.968), lactate dehydrogenase (p = 0.259) and interleukin 6 (p = 0.410). there were also no significant differences between the two groups with regards

Who reads Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia?

Author

Faryal Khamis; Hanan Al Naabi; Adil Al Lawati; Zaiyana Ambusaidi; Mariam Al Sharji; Umkulthum Al Barwani; Nenad Pandak; Zakariya Al Balushi; Maher Al Bahrani; Issa Al Salmi; Ibrahim Al-Zakwani

Publisher

Elsevier Science; Elsevier ; Elsevier BV (ISSN 1201-9712)

Published

2020

Language

EN

Field

Medicine (Health Sciences)